Matching articles for "retifanlimab"
Issue 1733 · July 21, 2025
Retifanlimab (Zynyz) for Anal Cancer (online only)

Retifanlimab-dlwr ( Zynyz – Incyte), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination with carboplatin and paclitaxel for first-line treatment of…

Med Lett Drugs Ther. 2025 Jul 21; 67(1733):e126-7 doi:10.58347/tml.2025.1733m
Retifanlimab-dlwr ( Zynyz – Incyte), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination with carboplatin and paclitaxel for first-line treatment of unresectable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) and as monotherapy in patients who had disease progression or intolerance to platinum-based chemotherapy. The drug received accelerated approval for treatment of recurrent locally advanced or metastatic Merkel cell carcinoma in 2023.
Issue 1674 · April 17, 2023 Free
In Brief: Retifanlimab (Zynyz) for Merkel Cell Carcinoma (online only)

Retifanlimab-dlwr ( Zynyz – Incyte), a programmed death receptor-1 (PD-1) blocking antibody, has received accelerated approval from the FDA for treatment of metastatic or recurrent locally advanced Merkel…

Med Lett Drugs Ther. 2023 Apr 17; 65(1674):e73-4 doi:10.58347/tml.2023.1674h
Retifanlimab-dlwr ( Zynyz – Incyte), a programmed death receptor-1 (PD-1) blocking antibody, has received accelerated approval from the FDA for treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in adults. Accelerated approval of the drug was based on the response rate and duration of response. Retifanlimab is the third drug to be approved in the US for treatment of MCC; pembrolizumab (Keytruda) , a PD-1 blocking antibody, is approved for the same indication as retifanlimab in patients ≥12 years old and avelumab (Bavencio) , a programmed death ligand-1 (PD-L1) blocking antibody, is approved for treatment of metastatic MCC in patients ≥12 years old.